Funded Tech Companies
Aeglea BioTherapeutics
Aeglea BioTherapeutics, operating out of Austin, raised money from Lilly Ventures, Novartis Venture Fund and Ally Bridge Group.
Company Overview
Company Name
Aeglea BioTherapeutics
Company Status
Publicly-held
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
901 S. MoPac Expy. Barton Oaks Plz. One 250
Austin, TX 78746
USA
Austin, TX 78746
USA
Phone
Website
Email Address
Company Background Information
Overview
Aeglea BioTherapeutics (NASDAQ: AGLE) is developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
Last Transaction
4/7/2016
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Company Investors
- Lilly Ventures (Armen Shanafelt)
- Novartis Venture Fund (Henry Skinner)
- Ally Bridge Group
- Cowen Capital Partners
- Venrock
- Rock Springs Capital
- RA Capital (Rajeev Shah)
- UT Horizon Fund
- KBI Biopharma
Browse more funded tech companies:
Aegle Therapeutics | Aelita Software
Share this article
About Our VC Deals Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs